Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Acta Paediatrica (Oslo, Norway : 1992)
|
December 26, 2006
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
U Ramaswami, S Wendt, G Pintos-Morell, et al.
QJM : Monthly Journal of the Association of Physicians
|
July 28, 2010
Fabry disease: a review of current management strategies
A Mehta, M Beck, F Eyskens, et al.
International Journal of Clinical Practice
|
August 31, 2006
Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey
O Lidove, U Ramaswami, R Jaussaud, et al.
Plos One
|
April 6, 2018
Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation
L Lavalle, A S Thomas, B Beaton, et al.
European Journal of Clinical Investigation
|
December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatment
M Beck, R Ricci, U Widmer, et al.
The British Journal of Dermatology
|
June 19, 2007
Fabry disease and the skin: data from FOS, the Fabry outcome survey
C H Orteu, T Jansen, O Lidove, et al.
Journal of Inherited Metabolic Disease
|
July 15, 2009
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)
S A Jones, Z Almássy, M Beck, et al.
Science (New York, N.Y.)
|
October 8, 2011
An activating mutation of AKT2 and human hypoglycemia
K Hussain, B Challis, N Rocha, et al.
Molecular Genetics and Metabolism
|
August 7, 2019
Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England
A Broomfield, J Davison, J Roberts, et al.
Pediatrics
|
November 11, 2009
Multidisciplinary management of Hunter syndrome
Joseph Muenzer, M Beck, C M Eng, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Acta Paediatrica (Oslo, Norway : 1992)
|
December 26, 2006
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
U Ramaswami, S Wendt, G Pintos-Morell, et al.
QJM : Monthly Journal of the Association of Physicians
|
July 28, 2010
Fabry disease: a review of current management strategies
A Mehta, M Beck, F Eyskens, et al.
International Journal of Clinical Practice
|
August 31, 2006
Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey
O Lidove, U Ramaswami, R Jaussaud, et al.
Plos One
|
April 6, 2018
Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation
L Lavalle, A S Thomas, B Beaton, et al.
European Journal of Clinical Investigation
|
December 21, 2004
Fabry disease: overall effects of agalsidase alfa treatment
M Beck, R Ricci, U Widmer, et al.
The British Journal of Dermatology
|
June 19, 2007
Fabry disease and the skin: data from FOS, the Fabry outcome survey
C H Orteu, T Jansen, O Lidove, et al.
Journal of Inherited Metabolic Disease
|
July 15, 2009
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)
S A Jones, Z Almássy, M Beck, et al.
Science (New York, N.Y.)
|
October 8, 2011
An activating mutation of AKT2 and human hypoglycemia
K Hussain, B Challis, N Rocha, et al.
Molecular Genetics and Metabolism
|
August 7, 2019
Ten years of enzyme replacement therapy in paediatric onset mucopolysaccharidosis II in England
A Broomfield, J Davison, J Roberts, et al.
Pediatrics
|
November 11, 2009
Multidisciplinary management of Hunter syndrome
Joseph Muenzer, M Beck, C M Eng, et al.
Page
of 2